Tumor avatars could personalize sarcoma therapy
NCT ID NCT07405346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if growing a patient's tumor cells in the lab (called organoids) can help doctors choose the most effective first-line chemotherapy for advanced leiomyosarcoma, a rare cancer of smooth muscle. About 50 adults aged 18-75 who have not yet received systemic treatment will be enrolled. The main goal is to improve the tumor shrinkage rate and delay cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.